Financial Data and Key Metrics Changes - For Q4 2025, general and administrative expenses were approximately $1.5 million, down from $1.6 million in Q4 2024. R&D expenses decreased to approximately $2.7 million from $4.3 million in the prior year [33] - The net loss for Q4 2025 was approximately $4.1 million, or $0.36 per share, compared to a net loss of approximately $5.9 million, or $0.54 per share for Q4 2024 [33] - For the full year 2025, R&D expenses were approximately $11.5 million, down from $16.1 million in 2024, while general and administrative expenses increased slightly to $6.5 million from $6.1 million [34] - The net loss for the full year 2025 was approximately $17.1 million, or $1.57 per share, compared to $20.8 million, or $1.93 per share for 2024 [36] Business Line Data and Key Metrics Changes - The LP-300 program is focused on lung cancer, specifically targeting never smokers with non-small cell lung cancer, representing a substantial market opportunity of over $4 billion annually [7][8] - The LP-184 phase I trial showed a 48% clinical benefit rate in heavily pretreated advanced cancer patients, validating the synthetic lethality hypothesis [10][11] - The company has dosed over 100 patients across its programs, indicating progress in clinical trials and potential future medicinal opportunities [5] Market Data and Key Metrics Changes - The combined estimated annual market potential for the company's AI-driven clinical pipeline exceeds $15 billion and approaches $20 billion [4] - The market for rare cancers and rare diseases is projected to exceed $300 billion by 2028, with the broader AI-enabled drug discovery market representing an additional $20 billion to $50 billion long-term opportunity [31] Company Strategy and Development Direction - The company is advancing its clinical programs and expanding the RADR platform's commercial reach globally through a new AI Center of Excellence in India [4] - The strategy includes leveraging AI and machine learning to transform drug development processes, aiming to reduce costs and timelines significantly [32] - The company plans to pursue additional funding and partnerships to support its clinical trials and expand its AI platform [40] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of AI technologies in transforming drug discovery and precision oncology, predicting significant returns for investors as the industry matures [2] - The company is focused on executing a dual engine strategy, advancing clinical assets while scaling its AI platform for commercial deployment [42] - Management expressed confidence in the potential for accelerated progress in cancer treatment due to advancements in AI [41] Other Important Information - The company has received FDA Orphan Drug Designation for multiple indications, which could provide pathways for FDA Priority Review Vouchers upon potential approval [17][22] - The IND clearance for the pediatric CNS cancer trial represents a significant milestone for the company's subsidiary, Starlight Therapeutics [16] Q&A Session Summary - No specific questions and answers were provided in the content, thus this section is not applicable.

Financial Data and Key Metrics Changes - For Q4 2025, the company reported a net loss of approximately $4.1 million, or $0.36 per share, compared to a net loss of approximately $5.9 million, or $0.54 per share, in Q4 2024, reflecting improved financial performance [31] - Full-year 2025 R&D expenses were approximately $11.5 million, down from approximately $16.1 million in 2024, primarily due to a reduction in research studies and materials [32] - The net loss for the full year 2025 was approximately $17.1 million, or $1.57 per share, compared to approximately $20.8 million, or $1.93 per share, for 2024, indicating a decrease in losses [33] Business Line Data and Key Metrics Changes - The company achieved clinical validation across multiple programs, including LP-300 and LP-184, with significant milestones in their clinical trials [3][4] - The LP-300 program is focused on a significant unmet need in lung cancer, particularly among never smokers, with a market opportunity estimated at over $4 billion annually [6] - The LP-184 phase I trial showed a 48% clinical benefit rate in heavily pretreated advanced cancer patients, validating the synthetic lethality hypothesis [9] Market Data and Key Metrics Changes - The estimated annual market potential for the company's AI-driven clinical pipeline exceeds $15 billion and approaches $20 billion [4] - The company is actively exploring global collaboration opportunities to maximize LP-300's commercial potential [9] Company Strategy and Development Direction - The company is positioning to advance clinical programs and expand the RADR platform's commercial reach globally through a new AI Center of Excellence in India [4] - The strategy includes leveraging AI and machine learning to transform drug development processes, aiming to reduce costs and timelines significantly [2][38] - The company plans to launch the withZeta platform, which integrates advanced AI capabilities for drug discovery, at the upcoming AACR conference [37] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of AI technologies in the future of medicine and drug development, predicting significant returns for investors and patients [2] - The company is focused on executing a dual engine strategy, advancing clinical assets while scaling the AI platform for commercial deployment [39] - Management expressed confidence in the potential for AI to accelerate drug development timelines and improve patient outcomes [38] Other Important Information - The company has received FDA Orphan Drug Designation for multiple programs, which could provide pathways for FDA Priority Review Vouchers upon potential approval [15][20] - The company reported a cash position of approximately $10.1 million as of December 31, 2025, and indicated the need for substantial additional funding in the near future [34] Q&A Session Summary - No specific questions or answers were provided in the content regarding the Q&A session.

Group 1: Company Overview - Lantern Pharma, Inc. (NASDAQ:LTRN) is a clinical-stage biopharmaceutical company focused on oncology drug discovery and development using artificial intelligence, machine learning, and genomics [7] - The company has established an Artificial Intelligence Center of Excellence and Advanced Agentic Labs in Bengaluru, India, aimed at scaling its proprietary RADR AI platform for global biopharma use [4] Group 2: Recent Developments - On January 20, the FDA granted Lantern Pharma's LP-284 an Orphan Drug Designation (ODD), which supports the development of treatments for diseases affecting fewer than 200,000 people [1][3] - This ODD designation for LP-284 is the third for this molecule, with previous designations for mantle cell lymphoma in January 2023 and high-grade B-cell lymphoma in November 2023 [3] Group 3: RADR AI Platform - The RADR platform integrates hundreds of billions of oncology-focused data points, sophisticated machine learning algorithms, and curated disease models to identify biomarkers, predict drug responses, and optimize clinical strategies [6] - The Bengaluru facility will serve as a global scale-up hub for RADR, expanding computational capacity and developing machine learning-ready disease models [5]

Core Insights - Palantir Technologies (NASDAQ: PLTR) has established itself as a leader in AI-driven data analytics, securing significant government contracts and expanding its intelligence business, resulting in a 105% stock price increase year-to-date, trading at $154 [1][2] Company Summaries BigBear.ai (NYSE: BBAI) - BigBear.ai is undergoing a strategic pivot, highlighted by its acquisition of Ask Sage, a generative AI platform for secure sectors like defense, which is expected to generate approximately $25 million in annual recurring revenue in 2025 [3][5] - The acquisition positions BigBear to transition from a decision-intelligence contractor to a full-stack generative AI provider, enhancing its offerings for government clients [4] - With over $450 million in cash, BigBear has the financial flexibility to support growth initiatives and strategic investments, potentially allowing it to carve out a unique position in the defense AI sector [5][6] Lantern Pharma (NASDAQ: LTRN) - Lantern Pharma utilizes its RADR AI platform to innovate oncology drug development, leveraging over 200 billion data points and 200 machine-learning algorithms [7] - The company has shown promising clinical results, with a 48% clinical benefit rate in its LP-184 Phase 1a trial among heavily pretreated patients [8][9] - Lantern is managing its cash effectively, with $19.7 million available, and plans to commercialize parts of its RADR platform, which could generate revenue through licensing [9]

Financial Data and Key Metrics Changes - R&D expenses decreased to approximately $2.4 million in Q3 2025 from $3.7 million in Q3 2024, primarily due to reductions in clinical trial support and consulting expenses [35] - General and administrative expenses increased to approximately $1.9 million in Q3 2025 from $1.5 million in the prior year, attributed to higher business development and investor relations costs [35] - The net loss for Q3 2025 was approximately $4.2 million, or $0.39 per share, compared to a net loss of approximately $4.5 million, or $0.42 per share in Q3 2024 [36] Business Line Data and Key Metrics Changes - The LP-184 phase 1a clinical trial achieved a 48% clinical benefit rate in evaluable cancer patients, validating the AI-driven precision medicine approach [5][11] - Preliminary phase II data from the LP-300 Harmonic trial showed an 86% clinical benefit rate, with one patient demonstrating a durable complete response for nearly two years [20][21] - The LP-284 program targeting recurrent non-Hodgkin's lymphoma generated interest from biopharma companies, showcasing a complete metabolic response in a heavily pretreated patient [23] Market Data and Key Metrics Changes - The combined annual market potential for the targeted indications of LP-184 exceeds $7 billion, with specific opportunities in triple-negative breast cancer, non-small cell lung cancer, bladder cancer, and recurrent GBM [17] - The market opportunity for the LP-300 program in lung cancer among never-smokers is approaching $4 billion annually, with no current approved therapies for this demographic [19] - The LP-284 program has a global market opportunity of about $3 billion, focusing on patients with aggressive recurrent non-Hodgkin's lymphoma [22] Company Strategy and Development Direction - The company is focused on integrating AI and machine learning into drug discovery and development, positioning itself as a leader in precision oncology [4][39] - The RADR AI platform is being commercialized, with eight distinct AI-powered modules developed to address critical pain points in oncology drug development [26][34] - The introduction of the Zeta platform aims to streamline rare cancer research and drug development, enhancing decision-making and reducing costs [30][32] Management's Comments on Operating Environment and Future Outlook - Management highlighted the transformative nature of the past quarter, achieving significant clinical, regulatory, and validation milestones [5] - The company expects to continue advancing its clinical assets while scaling its AI platform for commercial deployment, emphasizing a dual engine strategy [39][40] - Management expressed confidence in the potential of their AI tools and services to represent several hundred million dollars in standalone market potential [34] Other Important Information - As of September 30, 2025, the company had approximately $12.4 million in cash, cash equivalents, and marketable securities, providing a runway into approximately Q3 2026 [36] - The company entered into an ATM sales agreement to offer and sell up to $15.53 million of its common stock, raising approximately $989,000 during Q3 2025 [37] Q&A Session Summary Question: Update on interim event analysis for the LP-300 trial - Management indicated that they do not expect to reach the 31 events required for analysis until early 2026, which is seen as positive news as it suggests patients are remaining on the trial longer [41] Question: Status of the Denmark trial - The Denmark trial has been approved, with IRBs set and a project manager assigned, expected to start in late December or early January [42] Question: IND submission for the pediatric CNS program - Management confirmed readiness to submit the IND for the pediatric CNS program in the coming weeks [42] Question: Details on the Zeta platform - The Zeta platform is expected to have an interesting and bumpy early rollout, with internal usage already underway and plans for broader rollout in Q1 [43] Question: Indications for LP-184 - Management plans to identify the most impactful indications for larger scale trials, with interest from pharmaceutical companies [44]